Drug profile · INN
larotrectinib
VITRAKVI
larotrectinib (VITRAKVI) is a neurotrophic tyrosine kinase receptor inhibitor. Associated with Bayer Australia Ltd.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L01) L01XE53
Patents linked 0
Pipeline programs 4
News articles 1
Drug details — larotrectinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.83
Quick answer
larotrectinib (VITRAKVI) is a neurotrophic tyrosine kinase receptor inhibitor. Associated with Bayer Australia Ltd.
Key facts
INN larotrectinib
Brand VITRAKVI
Mechanism Neurotrophic tyrosine kinase receptor inhibitor
Target Neurotrophic tyrosine kinase receptor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XE53
Originator Bayer Australia Ltd
Mechanism of action
Neurotrophic tyrosine kinase receptor inhibitor
Primary target: Neurotrophic tyrosine kinase receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is larotrectinib?
larotrectinib (VITRAKVI) is a neurotrophic tyrosine kinase receptor inhibitor. Associated with Bayer Australia Ltd.
What is the brand name for larotrectinib?
VITRAKVI is a marketed brand name for larotrectinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.